Search
Isatin
go.drugbank.com/drugs/DB02095ExperimentalThe compound is found in many plants and Schiff bases of Isatin are have been investigated for pharmaceutical applications. … Isatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids.
Abdavomeran
go.drugbank.com/drugs/DB15695Investigational[L15012] BNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). … [L15012] The modRNA is formulated in lipid nanoparticles for delivery via intramuscular injection.
Pimivalimab
go.drugbank.com/drugs/DB16667InvestigationalPimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After
Pixatimod
go.drugbank.com/drugs/DB19166InvestigationalPixatimod is under investigation in clinical trial NCT05061017 (Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide … in MSS Metastatic Colorectal Carcinoma (Mcrc)).
Picafibrate
go.drugbank.com/drugs/DB19574ExperimentalPicafibrate is a small molecule drug. … The usage of the INN stem '-fibrate' in the name indicates that Picafibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.
Tiafibrate
go.drugbank.com/drugs/DB19874ExperimentalTiafibrate is a small molecule drug. … The usage of the INN stem '-fibrate' in the name indicates that Tiafibrate is a clofibrate derivative, peroxisome proliferator activated receptor-a (PPAR-a) agonist.
IDM-1
go.drugbank.com/drugs/DB05292ExperimentalIt is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc. … IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer.
SR-9009
go.drugbank.com/drugs/DB14013ExperimentalSR-9009 is a REV-ERB agonist. … SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
(S)-Warfarin
go.drugbank.com/drugs/DB14055InvestigationalS-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A7166] … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways.
Bempegaldesleukin
go.drugbank.com/drugs/DB15140InvestigationalBempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy